Author:
Ellero Andrea Antonio,van den Bout Iman,Vlok Maré,Cromarty Allan Duncan,Hurrell Tracey
Abstract
AbstractThree-dimensional models are considered a powerful tool for improving the concordance between in vitro and in vivo phenotypes. However, the duration of spheroid culture may influence the degree of correlation between these counterparts. When using immortalised cell lines as model systems, the assumption for consistency and reproducibility is often made without adequate characterization or validation. It is therefore essential to define the biology of each spheroid model by investigating proteomic dynamics, which may be altered relative to culture duration. As an example, we assessed the influence of culture duration on the relative proteome abundance of HepG2 cells cultured as spheroids, which are routinely used to model aspects of the liver. Quantitative proteomic profiling of whole cell lysates labelled with tandem-mass tags was conducted using liquid chromatography-tandem mass spectrometry (LC–MS/MS). In excess of 4800 proteins were confidently identified, which were shared across three consecutive time points over 28 days. The HepG2 spheroid proteome was divergent from the monolayer proteome after 14 days in culture and continued to change over the successive culture time points. Proteins representing the recognised core hepatic proteome, cell junction, extracellular matrix, and cell adhesion proteins were found to be continually modulated.
Funder
National Research Foundation
University of Pretoria
National Research Foundation, South Africa
Publisher
Springer Science and Business Media LLC
Reference65 articles.
1. Naci, H., Cylus, J., Vandoros, S., Sato, A. & Perampaladas, K. Raising the bar for market authorisation of new drugs. BMJ 345, e4261 (2012).
2. Wieseler, B., McGauran, N. & Kaiser, T. J. B. New drugs: Where did we go wrong and what can we do better?. BMJ 366, l4340 (2019).
3. Mullard, A. Parsing clinical success rates. Nat. Rev. Drug Discov. 15, 447 (2016).
4. Harrison, R. K. Phase II and phase III failures: 2013–2015. Nat. Rev. Drug Discov. 15, 817 (2016).
5. Babai, S., Auclert, L. & Le-Louët, H. Safety data and withdrawal of hepatotoxic drugs. Therapie 20, 20 (2018).
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献